J9395 Injection, fulvestrant
Also known as: fulvestrant, Faslodex
Injection of fulvestrant, a steroidal estrogen receptor antagonist. Used for hormone receptor-positive metastatic breast cancer.
In Plain Language
hormone-sensitive breast cancer injection; estrogen blocker
Clinical Context
Intramuscular injection for estrogen receptor-positive metastatic breast cancer. Often combined with CDK4/6 inhibitors for enhanced efficacy.
RVU Information
CPT J9395 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9395?
CPT J9395 (Injection, fulvestrant) is a J Codes (Drugs) code. Injection of fulvestrant, a steroidal estrogen receptor antagonist. Used for hormone receptor-positive metastatic breast cancer.
How is J9395 administered?
CPT J9395 is administered by a healthcare provider, typically via injection or infusion. Intramuscular injection for estrogen receptor-positive metastatic breast cancer. Often combined with CDK4/6 inhibitors for enhanced efficacy. It is used by Oncology, Surgery, Internal Medicine.
When is CPT J9395 used?
Intramuscular injection for estrogen receptor-positive metastatic breast cancer. Often combined with CDK4/6 inhibitors for enhanced efficacy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.